Low-Degree Polymer Conjugation on Blood Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic compositions for blood clotting disorders, such as hemophilia A and von Willebrand syndrome, face challenges due to the development of antibodies against administered blood factors, leading to reduced efficacy, and high degrees of water-soluble polymers like PEG can increase toxicity and immunological risks.
Innovation Solution
The development of chemically modified blood factor variants with low amounts of water-soluble polymers, specifically polysialic acid (PSA) or polyethylene glycol (PEG), attached to recombinant blood factors like Factor VIII through reductive amination or stable/linkable bonds, to enhance stability and half-life while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood factors are administered to treat hemophilia A and von Willebrand syndrome, then therapeutic efficacy is improved, but antibody formation increases leading to reduced efficacy
Solution Approach 1:
A water-soluble polymer (such as PEG or dextran) is used as an intermediary substance conjugated to the blood factor. This polymer mediator reduces the immunogenicity of the blood factor while maintaining its therapeutic activity, thereby decreasing antibody formation and improving treatment reliability
Solution Approach 2:
The invention creates a composite therapeutic agent by chemically conjugating a blood factor with a water-soluble polymer. This composite structure combines the therapeutic properties of the blood factor with the immunoprotective and pharmacokinetic benefits of the polymer, reducing antibody formation while maintaining efficacy
2Duration of action of moving object
If water soluble polymer is conjugated to blood factor to prolong half-life, then duration of action is improved, but toxicity and immunological risks increase
Solution Approach 1:
The invention optimizes the conjugation parameters including the ratio of polymer to blood factor, the molecular weight of the polymer, and the degree of substitution. By carefully controlling these parameters, the half-life is prolonged while keeping toxicity and immunological risks at acceptable levels
Solution Approach 2:
The water-soluble polymer is conjugated to specific regions or sites on the blood factor molecule rather than uniformly throughout. This localized conjugation strategy allows the polymer to provide pharmacokinetic benefits while minimizing interference with the blood factor's biological activity and reducing immunogenicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified blood factors demonstrate improved pharmacokinetics and reduced immunogenicity, allowing for lower dosing frequencies and increased therapeutic efficacy with reduced toxicity and antibody formation, effectively treating blood clotting disorders like hemophilia A and von Willebrand syndrome.
Implementation Method 1
water soluble polymer molecules, attached to recombinant blood factors like Factor VIII through reductive amination or stable/linkable bonds
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.